Condition 1: Sarcoma of bone and articular cartilage of limbs. Condition 2: Sarcoma of bone and articular cartilage of other and unspecified sites. Condition 3: Sarcoma of other connective and soft tissue. Malignant neoplasm of bone and articular cartilage of limbs Malignant neoplasm of bone and articular cartilage of other and unspecified sites Malignant neoplasm of other connective and soft tissue
Conditions
Interventions
Intervention 1: Intervention group: patients with sarcoma referred to Shohada Haftom Tir and Bu Ali medical centers who will receive Iscador drug based on a standardized dose, which is obtained from
Sponsors
Islamic Azad University
Eligibility
Sex/Gender
All
Age
10 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients with written consent Patients with soft tissue and bone sarcomas in different parts of the body, such as limbs, trunk, and head, who have indications for surgery Patients aged between 10 and 70 years
Exclusion criteria
Exclusion criteria: Patients who have not followed up or visited after surgery Those were already treated with Iscador's drug Pregnant and lactating people People unable to respond to the quality of life scale Concomitant treatment with steroids People who are allergic to medicines
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determining the effectiveness of Iscador in patients with sarcoma to improve the quality of life based on the EORTC QLQ C-30(European Organization for Research and Treatment of Cancer ,Quality of Life Questionnaire)criteria. Timepoint: During one year in each visit to follow up patients. Method of measurement: EORTC QLQ C-30(European Organization for Research and Treatment of Cancer ,Quality of Life Questionnaire).;Determining the effect of Iscador drug on the local control and recurrence of sarcoma tumors in the involved tissues. Timepoint: Follow-up of patients for one year according to standardized courses. Method of measurement: Imaging tools including Magnetic resonance imaging (MRI).;Determining the effect of Iscador drug in patients with sarcoma on post-surgical wound complications such as infection. Timepoint: Periodic follow-up after surgery until wound healing. Method of measurement: Based on the clinical examination of the wound site.;Determination of the effect of Iscador drug in patients with sarcoma in terms of safety according to side effects. Timepoint: During one year in each visit to follow up patients. Method of measurement: History, clinical examinations, tests and medical records of patients. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasoud Mirkazemi
Islamic Azad University
Outcome results
None listed